drugset / Trial / NCT05511051
A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy
Phase 2
Unknown
102 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hutchison Medipharma Limited · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The current study is to investigate the safety and efficacy of fruquintinib combined with HAIC in patients with advanced colorectal liver metastases who have failed second-line systemic standard treatment, in order to provide more survival opportunities for the second progression of advanced colorectal liver metastases.
Timeline
- Start
- 2022-02-01
- Primary completion
- 2024-08-01
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | 200 mg/m2 | Other |
| Subject | Oxaliplatin | Small molecule | 100 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 2000 mg/m2 | Other |
| Background | Fruquintinib | Small molecule | 5 mg | Oral |